CN109966171A - It is a kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation - Google Patents
It is a kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation Download PDFInfo
- Publication number
- CN109966171A CN109966171A CN201910351749.3A CN201910351749A CN109966171A CN 109966171 A CN109966171 A CN 109966171A CN 201910351749 A CN201910351749 A CN 201910351749A CN 109966171 A CN109966171 A CN 109966171A
- Authority
- CN
- China
- Prior art keywords
- composition
- apoptosis
- ultraviolet light
- inhibit
- light irradiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 230000006907 apoptotic process Effects 0.000 title claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 12
- 102000016938 Catalase Human genes 0.000 claims abstract description 8
- 108010053835 Catalase Proteins 0.000 claims abstract description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 7
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 7
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 6
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 6
- 229930195725 Mannitol Natural products 0.000 claims abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 6
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 6
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 6
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 6
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 6
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 6
- 239000011648 beta-carotene Substances 0.000 claims abstract description 6
- 229960002747 betacarotene Drugs 0.000 claims abstract description 6
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 235000010355 mannitol Nutrition 0.000 claims abstract description 6
- 239000000594 mannitol Substances 0.000 claims abstract description 6
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 6
- 239000011701 zinc Substances 0.000 claims abstract description 6
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 6
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 208000017520 skin disease Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 35
- 230000000694 effects Effects 0.000 abstract description 7
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract description 4
- 108010024636 Glutathione Proteins 0.000 abstract description 2
- 229960003180 glutathione Drugs 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000001678 irradiating effect Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 12
- 230000002285 radioactive effect Effects 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- HCAJQHYUCKICQH-UHFFFAOYSA-N 2-amino-9-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1C1CC(O)C(CO)O1 HCAJQHYUCKICQH-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229940119157 Hydroxy radical scavenger Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 206010041303 Solar dermatitis Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/27—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01006—Catalase (1.11.1.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cosmetics (AREA)
Abstract
Inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation the invention discloses a kind of.The composition includes: 10-200mg/ml acetylcysteine, 1-50mg/ml catalase, 1-10mg/ml histidine, 1-50ug/ml ubiquinone, 20-200ug/ml ascorbic acid, 5-50ug/ml beta carotene, 10-50ug/ml mannitol, 0.1-5ug/ml glutathione, 0.1-100ng/mL basic fibroblast growth factor, 0.1-2% zinc.The present invention can effectively inhibit Apoptosis caused by irradiating because of ultraviolet light using this composition, improve cell survival rate.The composition definite ingredients, use is safe, has significant effect and important application value on skin care item and skin treating drug.
Description
Technical field
The invention belongs to beauty and skin care technical fields, and in particular to a kind of to inhibit to lead to Apoptosis because of ultraviolet light irradiation
Composition, using polyphenoils, amino acid, the substances such as polypeptide remove free radical and protect cell, stablize eucaryotic cell structure, to reach
To the purpose of Regeneration and Repair skin.It is particularly suitable for the production preparation of cosmetics and skincare product.
Background technique
Apoptosis (apoptosis) refers to as ambient stable in maintaining, by autonomous orderly dead of the cell of gene control
It dies.Apoptosis is different from meronecrosis, and Apoptosis is the process of an active, is generated to changes in environmental conditions and stimulation
The death process that orderly changes of response.
The damage aging of skin be by cell problem caused by, ultraviolet light irradiation can accelerate the apoptosis of Skin Cell and old
Change, the variation of skin appearance can have drying, leatherization, follow the string, wrinkles and be often accompanied by irregular pigmentation etc.；Histology
On show as skin corium and thicken, it is indefinite form tissue that elastomer disorder, which is simultaneously finally degenerated,；Then, cause Photodermatoses,
Such as polygonal rash, farmer's skin, class Reticulocyte hyperplasia disease.Exceedingly being exposed to ultraviolet radioactive in short time can
To cause acute dermoreaction, including melanin is deepened, melanin granule migrates and generate increase (tanned) to surface, produces
Raw erythema (sunburn), the change of epidermal growth and pharmacological property photo sensitive reaction etc..
Ultraviolet light and radiation are the main assailants for causing skin aging and color spot.Mainly caused by several aspects:
1. ultraviolet radiation wave-lengths DNA, protein absorption peak near, DNA and Protein Damage can be caused；
2. ultraviolet radioactive can cause DNA damage electronics transfer and by way of generating free radicals；UVA ultraviolet light can be into
Enter skin corium, activates tyrosinase, so that melanocyte is divided out a large amount of pigment, destroy normal metabolic balance, cause
The deposition of color spot.
3. the structure due to cell membrane influences, attack of the Cell membrane lipids vulnerable to reactive oxygen intermediate.Ultraviolet radiation energy
Cell-membrane lipid bilayer Tiny sticky degree is caused to change.
4. including that amylase, catalase, pepsin and tyrosinase etc. can be inactivated by UVA and be one
A process for relying on oxygen.
It, can also be by antioxidant molecule and anti-oxidant for the damage of DNA either other cell components in terms of skin care
Enzyme greatly improves the removings of reactive intermediates, and exogenous catalase, hydroxy radical scavenger etc. can inhibit purple
The fracture of human fibroblasts DNA chain caused by outside line；Antioxidant can inhibit (the oxidative damage mark of 8-OH-dG in cell DNA
Will) formation；Histidine etc. can inhibit the lipid peroxidation of cytolipin plastid film；Acetylcysteine (NAC), can be in nothing
Postpone DNA replication dna under the premise of other cytotoxicities, so that increasing DNA repairs possibility and accuracy.In addition, microelement
Itself also has anti-ultraviolet radiation effect.(Ding Zhenhua, Fan Jianzhong, " ultraviolet radioactive biology and medicine ", the medical officer people publish
Society)
To sum up, using a series of ingredients such as polyphenoils, amino acid, polypeptide, reach anti-ultraviolet radiation, it is thin to remove free radical protection
Born of the same parents stablize eucaryotic cell structure etc., thus inhibit Apoptosis, Regeneration and Repair skin.
Summary of the invention
Inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation purpose of the present invention is to provide a kind of, to reach
The purpose of Regeneration and Repair skin.Reach beauty and skin care purpose from cell anti-apoptotic direction.
To achieve the above object, the present invention adopts the following technical scheme:
A kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation, the composition includes: final concentration of 10-
Acetylcysteine, 1-50mg/ml catalase, 1-10mg/ml histidine, the 1-50ug/ml ubiquinone, 20- of 200mg/ml
200ug/ml ascorbic acid, 5-50ug/ml beta carotene, 10-50ug/ml mannitol, 0.1-5ug/ml glutathione, 0.1-
The zinc of 100ng/mL basic fibroblast growth factor, mass fraction 0.1-2%.
The composition includes: the acetylcysteine of final concentration of 20mg/ml, 20mg/ml catalase, 3mg/
Ml histidine, 20ug/ml ubiquinone, 50ug/ml ascorbic acid, 30ug/ml beta carotene, 20ug/ml mannitol, 1ug/ml paddy
The sweet peptide of Guang, 10ng/mL basic fibroblast growth factor, mass fraction 1% zinc.
Further, by above-mentioned inhibition because ultraviolet light irradiation causes the composition of Apoptosis to be applied to prepare skin care item
In.
Further, by above-mentioned inhibition because ultraviolet light irradiation causes the composition of Apoptosis to be applied to prepare skin disease
In therapeutic agent.
The present invention has the advantages that
(1) inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation the present invention is to provide a kind of, utilize polyphenoils, ammonia
Base acid, the substances such as polypeptide remove free radical and protect cell, stablize eucaryotic cell structure, to achieve the purpose that Regeneration and Repair skin.
(2) material composition that the present invention utilizes is clear, safe and reliable；
(3) present invention changes from DNA damage, membrane structure, comprehensive design in terms of ultraviolet radioactive, inhibits to cause because of ultraviolet radioactive
Apoptosis.It can be widely used in drug, cosmetic industry.
Detailed description of the invention
Fig. 1 is to carry out cell activity counting by microscope, wherein A after ultraviolet radioactive: thin before 96 orifice plates of inoculation
Born of the same parents' state；B: negative control group, after ultraviolet irradiation, inverted microscope cell count；C: addition composition group, process are ultraviolet
After irradiation, inverted microscope cell count.(dead cell is navy blue by trypan blue dye, and living cells is not colored.)
1 fibroblast ultraviolet irradiation injury experiment of embodiment
1. experimental material: fibroblast HEF-1, the third generation derive from Healthy People.
2. experimental method:
(1) trypsinization collects human fibroblasts, is suspended in mass fraction 10wt%FBS DMEM/F12 culture medium
In, count cell number.Cell density is adjusted to 2.0 × 107Cells/mL, it is spare.
(2) it uses mass fraction 10wt%FBS DMEM/F12 culture medium as solvent, prepares the composition of embodiment 1, sufficiently
10wt%FBS DMEM/F12 composition culture medium is made in dissolution, spare.
(3) 2 1.5mL EP pipes are taken, are respectively designated as 1,2.Different culture mediums is separately added into according to following table.
The DMEM/F12 composition culture medium of mass fraction 10wt%FBS the preparation method comprises the following steps: utilizing mass fraction 10wt%
The DMEM/F12 of FBS is solvent, and acetylcysteine, the 20mg/ml catalase, 3mg/ of final concentration of 20mg/ml is added
Ml histidine, 20ug/ml ubiquinone, 50ug/ml ascorbic acid, 30ug/ml beta carotene, 20ug/ml mannitol, 1ug/ml paddy
The sweet peptide of Guang, 10ng/mL basic fibroblast growth factor, mass fraction 1% zinc, be completely dissolved after stirring, it is spare.
(4) two groups of cell suspensions are transferred to 96 different orifice plates respectively, every hole contains 20000 cells, total volume 100
µL.Cell is placed in 37 DEG C, 5wt%CO2Under the conditions of cultivate 12 hours overnight.
(5) culture medium is removed, the PBS buffer solution of pH 7.4 is added, 2 groups of cells are placed under ultraviolet lamp, irradiates 20 points
Clock siphons away buffer solution after irradiation, each that the corresponding culture medium of 1mL or composition culture medium is added.37 DEG C, 5wt%CO2Condition
It is incubated overnight 10-12 hours.
(6) trypsin digestion and cell, Trypan Blue, inverted microscope counting are taken pictures.
3. experimental result:
(1) negative control group cell counts (four quadrants):
Total number of cells: 128+142+131+116=515；
Dead cell sum: 56+70+67+52=245；
Cell activity: 52.0%.
(2) composition group cell counts (four quadrants) is added:
Total number of cells: 120+114+133+128=495；
Dead cell sum: 23+15+28+27=93；
Cell activity: 81.2%.
Fig. 1 is to carry out cell activity counting by microscope after ultraviolet radioactive.A: cellular before 96 orifice plates of inoculation
State；B: negative control group, after ultraviolet irradiation, inverted microscope cell count；C: addition composition group, by ultraviolet irradiation
Afterwards, inverted microscope cell count.(dead cell is navy blue by trypan blue dye, and living cells is not colored.)
The results show that composition group is added compared with negative control group (standard control), the two cell activity after ultraviolet irradiation
There is marked difference, illustrates to add damage of the composition group for inhibiting ultraviolet radioactive, Apoptosis is inhibited to have preferable effect.
The foregoing is merely presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification, is all covered by the present invention.
Claims (4)
1. a kind of inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation, it is characterised in that: the composition includes: end
Concentration is acetylcysteine, 1-50mg/ml catalase, the 1-10mg/ml histidine, 1-50ug/ml of 10-200mg/ml
Ubiquinone, 20-200ug/ml ascorbic acid, 5-50ug/ml beta carotene, 10-50ug/ml mannitol, 0.1-5ug/ml paddy Guang
Sweet peptide, 0.1-100ng/mL basic fibroblast growth factor, mass fraction 0.1-2% zinc.
2. a kind of inhibition according to claim 2 leads to the composition of Apoptosis because of ultraviolet light irradiation, it is characterised in that:
The composition includes: the acetylcysteine of final concentration of 20mg/ml, 20mg/ml catalase, 3mg/ml group ammonia
Acid, 20ug/ml ubiquinone, 50ug/ml ascorbic acid, 30ug/ml beta carotene, 20ug/ml mannitol, 1ug/ml gluathione
Peptide, 10ng/mL basic fibroblast growth factor, mass fraction 1% zinc.
3. -2 any compositions are preparing the application in skin care item according to claim 1.
4. -2 any compositions are preparing the application in treating skin disease drug according to claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910351749.3A CN109966171A (en) | 2019-04-28 | 2019-04-28 | It is a kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910351749.3A CN109966171A (en) | 2019-04-28 | 2019-04-28 | It is a kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109966171A true CN109966171A (en) | 2019-07-05 |
Family
ID=67086832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910351749.3A Pending CN109966171A (en) | 2019-04-28 | 2019-04-28 | It is a kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109966171A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101026965A (en) * | 2004-06-25 | 2007-08-29 | 费诺森股份有限公司 | Compositions suitable for treating cutaneous signs of aging |
| CN103207276A (en) * | 2012-12-31 | 2013-07-17 | 北京天辰空间生物医药研发有限公司 | Method of detecting inhibition of CoQ10 on UVB radiation damage |
| CN105396124A (en) * | 2015-11-30 | 2016-03-16 | 吉林省宝沪生物科技有限公司 | Medicine for treating ultraviolet-caused keratinocyte apoptosis |
-
2019
- 2019-04-28 CN CN201910351749.3A patent/CN109966171A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101026965A (en) * | 2004-06-25 | 2007-08-29 | 费诺森股份有限公司 | Compositions suitable for treating cutaneous signs of aging |
| CN103207276A (en) * | 2012-12-31 | 2013-07-17 | 北京天辰空间生物医药研发有限公司 | Method of detecting inhibition of CoQ10 on UVB radiation damage |
| CN105396124A (en) * | 2015-11-30 | 2016-03-16 | 吉林省宝沪生物科技有限公司 | Medicine for treating ultraviolet-caused keratinocyte apoptosis |
Non-Patent Citations (1)
| Title |
|---|
| 丁振华等: "《紫外辐射生物学与医学》", 30 November 2000, 人民军医出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | The water-soluble fullerene derivative ‘Radical Sponge®’exerts cytoprotective action against UVA irradiation but not visible-light-catalyzed cytotoxicity in human skin keratinocytes | |
| US20220175638A1 (en) | Cell activator | |
| Alemany-Ribes et al. | Toward a 3D cellular model for studying in vitro the outcome of photodynamic treatments: accounting for the effects of tissue complexity | |
| US20080058400A1 (en) | Skin external preparation | |
| CN106573055A (en) | Silicone-based biophotonic compositions and uses thereof | |
| CN105662905B (en) | Purposes of the dihydromyricetin in preparing prevention dermal photodamage skin care item or drug | |
| CN105030560A (en) | Protection effect of cyanidin-3-glucoside for UVB (ultraviolet B)-induced HaCaT cell injury | |
| CN106714837A (en) | Thermosetting biophotonic compositions and uses thereof | |
| CN108601718A (en) | For protecting skin to prevent composition of pollution effect and application thereof | |
| CN117547524A (en) | New application of germacrone compound | |
| CN109966171A (en) | It is a kind of to inhibit to lead to the composition of Apoptosis because of ultraviolet light irradiation | |
| JP5892576B2 (en) | Method for producing epithelial reconstructed body and screening method using the epithelial reconstructed body | |
| Khan et al. | Bryostatin and its synthetic analog, picolog rescue dermal fibroblasts from prolonged stress and contribute to survival and rejuvenation of human skin equivalents | |
| CN106687151A (en) | Emissive polymeric matrices | |
| Blinova et al. | Effect of melanins from black yeast fungi on proliferation and differentiation of cultivated human keratinocytes and fibroblasts | |
| Duan et al. | Handelin Reduces Ultraviolet A-Induced Photoaging by Inhibiting Reactive Oxygen Species Generation and Enhancing Autophagy | |
| CN113683662B (en) | Polypeptide for protecting ultraviolet skin damage | |
| ITTO20080585A1 (en) | COSMETIC COMPOSITION AND COSMETIC PROCEDURE FOR THE GROWTH OF TEGUMENTARY EQUIPMENT | |
| Zhou et al. | Modulating the photo-exciting process of photosensitizer to improve in vitro phototoxicity by preparing its self-assembly nanostructures | |
| CN111067893A (en) | Composition and application thereof in preparation of skin repair product | |
| Smith et al. | Exposure of 3T3 mouse fibroblasts and collagen to high intensity blue light | |
| CN112402608B (en) | Application of 5-alkoxy indole-3-vinyl quinoline salt as targeted migratable photosensitizer | |
| CN109010094A (en) | A kind of resveratrol beautifying face and moistering lotion cosmetics and preparation method | |
| CN116327627B (en) | Tetrahedral framework nucleic acid-glabridin complex and application thereof in skin whitening | |
| Anthony | To What Extent Does The Role Of Mitochondria Affect The Life And Death Of Human Skin Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |